Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 16/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991213 | 0.83 | BACE1 (0.66) | BACE1BACE2APP | |
| SCHEMBL1993065 | 0.82 | BACE1 (0.57) | BACE1BACE2 | |
| SCHEMBL1990013 | 0.82 | BACE1 (0.56) | BACE1BACE2APP | |
| SCHEMBL1997529 | 0.81 | BACE1 (0.65) | BACE1BACE2 | |
| SCHEMBL1994163 | 0.80 | BACE1 (0.64) | BACE1BACE2APP | |
| SCHEMBL1997865 | 0.80 | BACE1 (0.56) | BACE1BACE2APP | |
| SCHEMBL1994805 | 0.80 | BACE1 (0.65) | BACE1BACE2APP | |
| SCHEMBL1991286 | 0.79 | BACE1 (0.57) | BACE1BACE2APP | |
| SCHEMBL1992666 | 0.77 | BACE1 (0.68) | BACE1BACE2 | |
| SCHEMBL12565340 | 0.77 | BACE1 (0.48) | BACE1BACE2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318416-B1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8501733-B2 | Spiroaminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501733-B2 | Spiroaminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-06-23 | — | — | US | disclosed |
| WO-2010013794-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885APP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.